Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

VX18-147-001

36 evidence topics · 1 source

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics pooled across Study 1 and Study 2
CharacteristicPlacebo (N = 44)Inaxaplin total (N = 134)
Male, n (%)“41 (93.2)”View highlighted excerpt for this quote“128 (95.5)”View highlighted excerpt for this quote
Female, n (%)“3 (6.8)”View highlighted excerpt for this quote“6 (4.5)”View highlighted excerpt for this quote
Age (years), mean (±SD)“36.7 (11.3)”View highlighted excerpt for this quote“36.6 (11.6)”View highlighted excerpt for this quote
BMI (kg/m2), mean (±SD)“27.07 (3.14)”View highlighted excerpt for this quote“26.22 (3.30)”View highlighted excerpt for this quote
White, n (%)“30 (68.2)”View highlighted excerpt for this quote“94 (70.1)”View highlighted excerpt for this quote
Black or African American, n (%)“12 (27.3)”View highlighted excerpt for this quote“32 (23.9)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“1 (0.7)”View highlighted excerpt for this quote
American Indian or Alaska Native, n (%)“0”View highlighted excerpt for this quote“3 (2.2)”View highlighted excerpt for this quote
Multiracial, n (%)“1 (2.3)”View highlighted excerpt for this quote“4 (3.0)”View highlighted excerpt for this quote
Other race, n (%)“1 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“10 (22.7)”View highlighted excerpt for this quote“21 (15.7)”View highlighted excerpt for this quote
Not Hispanic or Latino, n (%)“34 (77.3)”View highlighted excerpt for this quote“113 (84.3)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events in the MAD cohorts of Study 1
n (%)Placebo (N = 9)Inaxaplin 15 mg once daily (N = 9)Inaxaplin 15 mg twice daily (N = 9)Inaxaplin 45 mg once daily (N = 9)Inaxaplin total (N = 27)
Participants with any AEs“2 (22.2)”View highlighted excerpt for this quote“4 (44.4)”View highlighted excerpt for this quote“5 (55.6)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“10 (37.0)”View highlighted excerpt for this quote
Mild AEs“2 (22.2)”View highlighted excerpt for this quote“4 (44.4)”View highlighted excerpt for this quote“5 (55.6)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“10 (37.0)”View highlighted excerpt for this quote
Moderate AEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Participants with SAEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
AEs leading to treatment discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Fatigue“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Cough“0”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Dyspepsia“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (11.1)”View highlighted excerpt for this quote
Constipation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Oropharyngeal pain“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Throat irritation“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Rhinorrhea“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Sneezing“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Study limitations
Summary: study limitations

VX18-147-001 enrolled healthy adults, so its safety findings do not describe people with APOL1-mediated kidney disease. Multiple dosing lasted 14 days, and each MAD group of Study 1 had 9 participants receiving inaxaplin (15 mg once daily, 15 mg twice daily, or 45 mg once daily) and 9 receiving pooled placebo. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. The publication reports demographics, disposition, and the overall adverse event table pooled across Study 1 and Study 2, and gives the pharmacokinetic parameter estimates, including the midazolam interaction results, only in online supplementary tables. The trials were designed and funded by Vertex Pharmaceuticals, and four of the authors are Vertex employees who own stock or stock options in the company.